Kim Hyo Kee, Jun Heungman, Ko Sun-Young
Department of Surgery, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
Department of Surgery, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
BMC Nephrol. 2025 Jan 2;26(1):2. doi: 10.1186/s12882-024-03924-0.
The 2019 Kidney Disease Outcome Quality Initiative guidelines emphasize the importance of selecting dialysis based on the life expectancy of the patient. However, it is difficult to predict the life expectancy of a patient during arteriovenous fistula creation. We investigated whether neutrophil-to-lymphocyte, monocyte-to-lymphocyte, and platelet-to-lymphocyte ratios measured before dialysis could predict mortality.
Between January 2016 and December 2020, we retrospectively analyzed electronic medical records of 448 patients aged ≥ 70 years undergoing first-time arteriovenous access surgery at three tertiary care hospitals, all of whom had not received prior dialysis treatment. Only patients undergoing blood tests on the day before surgery were included in the analysis. Patients who died within one year after surgery were included in the non-survival group, while those who died after one year were included in the survival group.
Patients were categorized into non-survival (n = 52) and survival (n = 396) groups. Multivariate analysis for one-year mortality revealed that the preoperative neutrophil-to-lymphocyte ratio demonstrated a 1.15 hazard ratio ( p < 0.001 ). Also, cancer (HR 2.50, p = 0.02) and peripheral arterial disease (HR 4.62, p < 0.001) were risk factor for one-year mortality. The preoperative platelet-to-lymphocyte and monocyte-to-lymphocyte ratios were not identified as one-year mortality risk factors. In the total mortality multivariate analysis, monocyte-to-lymphocyte ratios were one of the risk factors (HR 2.74, p < 0.007).
The neutrophil-to-lymphocyte ratio was a risk factor associated with one-year mortality in patients aged ≥ 70 years. However, further research is required to determine whether these can be used for predictive purposes.
2019年肾脏疾病预后质量倡议指南强调了根据患者预期寿命选择透析方式的重要性。然而,在动静脉内瘘建立过程中很难预测患者的预期寿命。我们研究了透析前测量的中性粒细胞与淋巴细胞比值、单核细胞与淋巴细胞比值以及血小板与淋巴细胞比值是否能够预测死亡率。
2016年1月至2020年12月期间,我们回顾性分析了三家三级医疗中心448例年龄≥70岁、首次接受动静脉通路手术且均未接受过透析治疗患者的电子病历。仅纳入手术前一天进行血液检查的患者。术后一年内死亡的患者纳入非存活组,术后一年后死亡的患者纳入存活组。
患者分为非存活组(n = 52)和存活组(n = 396)。对一年死亡率的多因素分析显示,术前中性粒细胞与淋巴细胞比值的风险比为1.15(p < 0.001)。此外,癌症(HR 2.50,p = 0.02)和外周动脉疾病(HR 4.62,p < 0.001)是一年死亡率的危险因素。术前血小板与淋巴细胞比值和单核细胞与淋巴细胞比值未被确定为一年死亡率的危险因素。在总死亡率的多因素分析中,单核细胞与淋巴细胞比值是危险因素之一(HR 2.74,p < 0.007)。
中性粒细胞与淋巴细胞比值是≥70岁患者一年死亡率的相关危险因素。然而,是否可将这些指标用于预测目的还需要进一步研究。